WO2012037158A2 - Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy - Google Patents
Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy Download PDFInfo
- Publication number
- WO2012037158A2 WO2012037158A2 PCT/US2011/051448 US2011051448W WO2012037158A2 WO 2012037158 A2 WO2012037158 A2 WO 2012037158A2 US 2011051448 W US2011051448 W US 2011051448W WO 2012037158 A2 WO2012037158 A2 WO 2012037158A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- radiation
- thymidine
- ribo
- deoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 122
- 230000000475 sunscreen effect Effects 0.000 title claims description 118
- 239000000516 sunscreening agent Substances 0.000 title claims description 118
- 238000004128 high performance liquid chromatography Methods 0.000 title claims description 56
- 238000011156 evaluation Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 190
- 230000005855 radiation Effects 0.000 claims abstract description 100
- 230000006378 damage Effects 0.000 claims abstract description 19
- 238000012360 testing method Methods 0.000 claims abstract description 13
- 230000003278 mimic effect Effects 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 87
- 230000004224 protection Effects 0.000 claims description 68
- 108020004414 DNA Proteins 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 37
- 239000002773 nucleotide Substances 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 32
- 108091034117 Oligonucleotide Proteins 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- -1 heterocyclic amine Chemical class 0.000 claims description 27
- 229940104230 thymidine Drugs 0.000 claims description 26
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 24
- 229960005305 adenosine Drugs 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 24
- 230000005778 DNA damage Effects 0.000 claims description 22
- 231100000277 DNA damage Toxicity 0.000 claims description 22
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
- 230000003902 lesion Effects 0.000 claims description 20
- 229940045145 uridine Drugs 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 238000006303 photolysis reaction Methods 0.000 claims description 12
- 230000015843 photosynthesis, light reaction Effects 0.000 claims description 12
- 230000037072 sun protection Effects 0.000 claims description 11
- 239000003208 petroleum Substances 0.000 claims description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 9
- 239000002777 nucleoside Substances 0.000 claims description 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 9
- XWLVCCHVHXBFBC-SXBJJNBASA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XWLVCCHVHXBFBC-SXBJJNBASA-N 0.000 claims description 8
- CPXIIHVUIFVTLA-YOCMHDSMSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=N)=C2N=C1.C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O CPXIIHVUIFVTLA-YOCMHDSMSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 8
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 8
- 229940029575 guanosine Drugs 0.000 claims description 8
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 238000013537 high throughput screening Methods 0.000 claims description 6
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 5
- 229910052753 mercury Inorganic materials 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000010453 quartz Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- YMXFJTUQQVLJEN-UHFFFAOYSA-N pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1 YMXFJTUQQVLJEN-UHFFFAOYSA-N 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 2
- 230000009946 DNA mutation Effects 0.000 claims 1
- 238000002474 experimental method Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 17
- 208000000453 Skin Neoplasms Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 201000000849 skin cancer Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000036555 skin type Effects 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 3
- 108091093078 Pyrimidine dimer Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003990 molecular pathway Effects 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008832 photodamage Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108030003599 (6-4)DNA photolyases Proteins 0.000 description 2
- VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 2
- MVUXHPCRYQXXTI-UHFFFAOYSA-N C1=CN=CN=C1.C1=CN=CN=C1.CC1=CNC(=O)NC1=O.CC1=CNC(=O)NC1=O Chemical class C1=CN=CN=C1.C1=CN=CN=C1.CC1=CNC(=O)NC1=O.CC1=CNC(=O)NC1=O MVUXHPCRYQXXTI-UHFFFAOYSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical group C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000000077 insect repellent Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000036561 sun exposure Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710188106 SEC14-like protein 2 Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/631—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited using photolysis and investigating photolysed fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/30—Characterised by physical treatment
- C12Q2523/313—Irradiation, e.g. UV irradiation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/313—Branched oligonucleotides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8827—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Definitions
- Sunlight plays many important roles for all organisms. Appropriate dosage of sunlight has tremendous biological benefits, such as photosynthesis in plants and vitamin D3 production in human skin [Nemanic MK, Whitney J, Arnaud S, Herbert S, Elias PM. Vitamin D3 production by cultured human keratinocytes and fibroblasts. Biochem Biophys Res Commun 1983 ; 115:444-50; Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin utr 2004;80: 1678S-88S], especially from exposure to ultraviolet (UV) B radiation. However, overexposure to sunlight will have devastating effects, such as cancer formation [Marrot L, Meunier JR.
- DNA, light and Dewar pyrimidinones the structure and biological significance of TpT3.
- UVA-induced cyclobutane pyrimidine dimers form predominantly at thymine-thymine dipyrimidines and correlate with the mutation spectrum in rodent cells.
- UV ultraviolet radiation
- radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject
- exposing said radiation diagnostic composition to said UV which passes through one or more protection compositions where said protection composition is positioned between said radiation diagnostic composition and said UV
- analyzing DNA damage of said radiation diagnostic composition comprising the steps of: (a) providing an ultraviolet radiation (UV); (b) providing one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; (c) exposing said radiation diagnostic composition to said UV which passes through one or more protection compositions where said protection composition is positioned between said radiation diagnostic composition and said UV; and (d) analyzing DNA damage of said radiation diagnostic composition.
- UV ultraviolet radiation
- Also disclosed are systems comprising: (a) a first device to generate ultraviolet radiation; (b) a second device to hold one or more protection compositions; (c) a third device to contain one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; and (d) a fourth device to analyze DNA damage of said radiation diagnostic composition; wherein said second device is interposed between said first device and said third device, and said third device is interposed between said second device and said fourth device.
- compositions comprising one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same, which is/are
- FIG. 1 shows that thymidine-thymidine (TT) dinucleotide is sensitive to UV irradiation where various photolesions are formed under the UV irradiation. Structures of native and damaged thymidine-thymidine (TT) dinucleotides: Native TT dinucleotide (A), cis-syn photolesion (B), and (6-4) photolesion (C). [0011] Figure 2 shows a representative flowchart of ultraviolet (UV) irradiation of natural thymidine-thymidine dinucleotide followed by high-performance liquid chromatography (HPLC) and UV analyses.
- UV ultraviolet
- FIG. 3 shows an example of protection of thymidine-thymidine dinucleotide by sunscreens against ultraviolet (UV) damage.
- UV irradiation for 0, 10, 30, and 60 minutes without sunscreen protection (control) (1); and using sunscreen with sun protection factor (SPF) 15 (2); 30 (3); 45 (4); and 70 (5).
- SPDF sun protection factor
- FIG 4 shows an example of Thymidine-thymidine dinucleotide protection by sunscreens against ultraviolet (UV) damage.
- UV irradiation for 60 minutes in presence and absence of sunscreens (sun protection factor [SPF] 15, 30, and 70): cyan bar, Control experiment; black bar, diluted sunscreens; and gray bar, undiluted sunscreens.
- SPDF sunscreen protection factor
- Figure 5 shows an example of High-performance liquid chromatography (HPLC) analysis of samples without sunscreen protection before and after ultraviolet irradiation.
- HPLC High-performance liquid chromatography
- Profiles A to D are from a sample without irradiation, monitored by HPLC at 250, 260, 290, and 326 nm, respectively.
- Profiles E to H are from the same sample irradiated for 60 minutes, monitored by HPLC at 250, 260, 290, and 326 nm, respectively.
- FIG. 6 shows an example of High-performance liquid chromatography (HPLC) analysis of the sample after 60-minute ultraviolet irradiation.
- HPLC profile of the sample monitored at 260 nm (A) and 326 nm (B).
- E Coinjection of the irradiated sample and TT (6-4) lesion monitored by HPLC at 326 nm
- FIG. 7 shows an example of High-performance liquid chromatography (HPLC) analysis of dinucleotide samples ultraviolet irradiated in presence or absence of sunscreen.
- Profiles A to C are from 0-, 10-, and 60-minute, respectively, irradiated samples without sunscreen, monitored by HPLC at 260 nm.
- Profiles D and E are from 10- and 60-minute, respectively, irradiated samples without sunscreen, monitored by HPLC at 326 nm.
- Profiles F and G are from 60-minute irradiated sample protected by sun protection factor (SPF) 70, monitored at 260 nm and 326 nm, respectively.
- SPF sun protection factor
- UVB sun protection factor is normally assigned to different sunscreens products according to their sun protection effectiveness as determined by complicated strategies [systems and methods; Bissonnette R, Alias S, Moyal D, Provost N. Comparison of UVA protection afforded by high sun protection factor sunscreens. J Am Acad Dermatol
- UV irradiation of nucleic acids formation, purification and solution conformational analysis of the '6-4 lesion' of dTpdT. Nucleic Acids Res 1985; 13 :5949-63], and it forms various photolesions (including the deadly 6-4 photolesion), disclosed are simple methods using, in vitro nucleic acid molecules, such as a TT dinucleotide, radiation production and spectrophotometry, such as UV
- UV-HPLC systems that allow easy monitoring of the formation of various photolesions formed during the UV irradiation, for example, the thymidine (6-4) photolesion (pyrimidine(6-4) pyrimidone photoproduct), which is very mutagenic and has characteristic absorption at 320 nm.
- the disclosed systems can be combined with traditional components of a synthetic TT dinucleotide (mimic of photosensitive DNA) and UV lamp (mimic of sunlight) to analyze commercially available sunscreens.
- the disclosed methods and systems are simple sunscreen-analysis methods and systems, which are designed using nucleic acids, such as thymidinethymidine dinucleotides, ultraviolet spectrophotometer or highperformance liquid chromatography, or ultraviolet spectrophotometer and high performance liquid chromatography, avoids the use of human subjects to analyze the effectiveness of sunscreens.
- the disclosed radiation such as ultraviolet and/or high-performance liquid chromatography methods and systems, can directly monitor types of DNA photolesions that are formed.
- the disclosed sunscreen-analysis methods and system provide assistance in choosing the most effective sunscreens for the skin health of consumers.
- Disclosed are methods comprising the steps of: (a) providing a radiation, such as an ultraviolet radiation (UV); (b) providing one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; (c) exposing said radiation diagnostic composition to said UV which passes through one or more protection compositions where said protection composition is positioned between said radiation diagnostic composition and said radiation, such as UV; and (d) analyzing DNA damage of said radiation diagnostic composition.
- a radiation such as an ultraviolet radiation (UV)
- UV ultraviolet radiation
- methods which further comprise the step of identifying a protection composition that reduces and/or prevents ultraviolet (UV) radiation- caused DNA damage in a subject.
- the step of identifying comprises assaying the presence of mutations in said radiation diagnostic composition.
- methods which further comprise the step of screening efficacy of one or more protection compositions in reducing and/or preventing ultraviolet (UV) radiation-caused DNA damage in a subject.
- protection composition is sunscreen formulation, cosmetic formulation or a combination of sunscreen formulation and cosmetic formulation.
- step (d) comprises performing the analysis of DNA damage by ultraviolet spectrophotometer, High- performance liquid chromatography (HPLC), or a combination of said ultraviolet
- said radiation diagnostic composition comprises one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
- oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same.
- said radiation diagnostic composition comprises one or more dinucleotides in deoxy- and/or ribo- series, and/or deoxy- ribo hybrids.
- Said dinucleotide comprises thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
- TT thymidine-thymidine
- TC thymidine-gua
- said radiation diagnostic composition is dissolved in a solvent.
- said solvent comprises water, acetonitrile, or a mixture of water and acetonitrile.
- said solvent is a mixture of water and acetonitrile and the volume ratio between water and acetonitrile is from about 1 :20 to about 20: 1.
- said volume ratio between water and acetonitrile is from about 1 :9 to about 9: 1.
- said protection composition is provided in an amount of from about 0.01 mg to about 50 g. In some other forms, said protection composition is provided and/or applied directly on a surface in an amount of from about 2 mg to about 200 mg. In some other forms, said protection composition is directly applied on a transparent surface (or support) that is placed between said radiation diagnostic composition and said UV. In some other forms, disclosed are methods wherein said protection composition is dissolved in a solvent. In some forms, disclosed are methods wherein said solvent comprises water, petroleum ether, or a mixture of water and petroleum ether. In some other forms, disclosed are methods wherein said mixture of water and petroleum ether has a volume ratio between water and petroleum ether from about 1 :20 to about 20: 1.
- said protection composition is dissolved in a solvent with a concentration of from about 0.01 mg/mL to about lOOOmg/mL. In other forms, said protection composition is dissolved in a solvent with a concentration of from about 1 mg/ml to about 500mg/ml. In still some other forms, said protection composition is dissolved in a solvent with a concentration of from about 50 mg/ml to about 200mg/ml.
- said protection composition is a sunscreen formulation.
- said sunscreen formulation has a sun protection factor (SPF) of from about 10 to about 100.
- SPDF sun protection factor
- said sunscreen formulation has a SPF of about 15, 30, 45, or 70.
- DNA damage comprises formation of DNA lesion.
- said DNA lesion comprises cis-syn, trans-syn, TT pyrimidine (6-4) pyrimidone, Dewar pyrimidine-pyrimidine photolesion, or a mixture of the same.
- said DNA lesion comprises TT pyrimidine (6-4) pyrimidone photolesion.
- RNA damage of said radiation diagnostic composition is conducted by monitoring the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in said radiation diagnostic composition after said radiation diagnostic composition is exposed to UV for a predetermined period of time.
- analysis of said DNA damage of said radiation diagnostic compositions is conducted by monitoring the amount of TT dinucleotide preserved in said radiation diagnostic composition after said radiation diagnostic composition is exposed to UV for a predetermined period of time.
- methods wherein the UV- irradiated radiation diagnostic composition is analyzed by ultraviolet spectrophotometer and/or HPLC at wavelength of 250, 260, 290, 326 nm or a combination of the same.
- a representative ultraviolet absorption of TT pyrimidine (6-4) pyrimidone photolesion is at about 326 nm. In some other forms, disclosed are methods wherein a representative ultraviolet absorption of TT dinucleotide is at about 260 nm.
- a representative residence time of TT pyrimidine (6-4) pyrimidone photolesion in the HPLC is at about 1 1.2 minutes. In other forms, disclosed are methods wherein a representative residence time of TT dinucleotide in the HPLC is at about 15.9 minutes. In some forms, disclosed are methods wherein monitoring of the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in the UV-irridiated radiation diagnostic composition is conducted at one or more time intervals selected from the group consisting of 0, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180 and 240 minutes.
- TT pyrimidine (6-4) pyrimidone photolesion fromed in the UV-irridiated radiation diagnostic composition and/or the amount of TT dinucleotide preserved in the UV-irridiated radiation diagnostic composition.
- disclosed are methods wherein said efficacy of said protection composition as obtained from said method is consistent to SPF ranking of commercial sunscreens. In some other forms, disclosed are methods wherein said efficacy of said protection composition can be obtained without the use of human or animal subject. In some forms, disclosed are methods wherein said efficacy of said protection composition can be obtained within less than about 5, 10, 20, 30, 45, 60, 90 or 120 minutes. In some other forms, disclosed are methods wherein said testing of efficacy can be repeated with reliable results.
- testing of efficacy can be cross- validated on different radiation diagnostic compositions and/or subjects.
- methods wherein said testing of efficacy can be applied to a high-throughput screening for sunscreens.
- said high-throughput screening for sunscreens comprises testing a plurality of sunscreens simultaneously or sequentially.
- said plurality of sunscreens comprises from about 5 to about 100,000 sunscreens.
- methods wherein said subject is a mammal.
- Disclosed are systems comprising: (a) a first device to generate ultraviolet radiation; (b) a second device to hold one or more protection compositions; (c) a third device to contain one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; and (d) a fourth device to analyze DNA damage of said radiation diagnostic composition; wherein said second device is interposed between said first device and said third device, and said third device is interposed between said second device and said fourth device.
- said first device is an ultraviolet lamp.
- said first device is a low- pressure mercury lamp with emission ⁇ about 257 nm.
- said second device is a photolysis tube.
- said second device is a photolysis tube having a quartz filter with 200-nm cutoff.
- said third device is a cuvette.
- said fourth device is an ultraviolet spectrophotometer, High-performance liquid chromatography (HPLC), or a combination of said ultraviolet spectrophotometer and said HPLC.
- said radiation diagnostic composition comprises one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same.
- said radiation diagnostic composition comprises one or more dinucleotides in deoxy- and/or ribo- series.
- Said dinucleotide comprise thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine- guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
- TT thymidine-thymidine
- TC thymidine-cytidine
- TG thymidine
- radiation diagnostic compositions comprise one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
- oligonucleotides in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same, which is/are dissolved in a suitable solvent with a suitable concentration.
- said radiation diagnostic compositions comprising one or more dinucleotides in deoxy- and/or ribo- series and/or deoxy-ribo hybrids.
- Said dinucleotide comprise thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine- guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
- TT thymidine-thymidine
- TC thymidine-cytidine
- TG thymidine- guanosine
- TA thymidine-adenosine
- TU uridine-
- compositions wherein said suitable solvent is water, acetonitrile, or a mixture of water and acetonitrile with a suitable volume ratio.
- said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is from about 1 :20 to about 20: 1.
- said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is from about 1 :9 to about 9: 1.
- compositions wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is about 1 :9.
- said suitable concentration is from about 0.01 mmol/L to about 0.5 mmol/L.
- said suitable concentration is about 0.05 mmol/L.
- compositions wherein said composition can mimic DNA in cells of a subject and be used as a substrate in testing efficacy of one or more formulations in reducing and/or preventing from ultraviolet radiation (UV) caused DNA damage of said subject.
- UV ultraviolet radiation
- cell as used herein also refers to individual cells, cell lines, or radiation diagnostic compositions derived from such cells.
- a “culture” refers to a composition comprising isolated cells of the same or a different type. The term co-culture is used to designate when more than one type of cell are cultured together in the same dish with either full or partial contact with each other.
- composition of matter stand equally well for the chemical entities described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms “compound,” “analog,” and “composition of matter” are used interchangeably throughout the present specification.
- control or "control levels” or “control cells” are defined as the standard by which a change is measured, for example, the controls are not subjected to the experiment, but are instead subjected to a defined set of parameters, or the controls are based on pre- or post- treatment levels. They can either be run in parallel with or before or after a test run, or they can be a pre-determined standard.
- basal levels are normal in vivo levels prior to, or in the absence of, or addition of an agent such as an agonist or antagonist to activity.
- decreases or increases can be used to describe the binding of a molecule to a receptor.
- decreases would describe a situation of where the binding could be defined as having a Kd of 10 "9 M, if this interaction decreased, meaning the binding lessened, the Kd could decrease to 10 "6 M. It is understood that wherever one of these words is used it is also disclosed that it could be 1%, 5%, 10%, 20%, 50%, 100%, 500%, or 1000% increased or decreased from a control.
- inhibit or other forms of inhibit means to hinder or restrain a particular characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to.
- inhibits phosphorylation means hindering or restraining the amount of phosphorylation that takes place relative to a standard or a control.
- maintaining refers to continuing a state.
- maintaining can be refer to less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.1% change from a control, such a basal level, often a level in the absence of a treatment or in the presence of tretament with a placebo or standard.
- Material is the tangible part of something (chemical, biochemical, biological, or mixed) that goes into the makeup of a physical object.
- modulate or like terms refers to its standard meaning of increasing or decreasing.
- a substance or like terms is any physical object.
- a material is a substance.
- Molecules, ligands, markers, cells, proteins, DNA and RNA can be considered substances.
- a machine or an article would be considered to be made of substances, rather than considered a substance themselves.
- molecule refers to a biological or biochemical or chemical entity that exists in the form of a chemical molecule or molecule with a definite molecular weight.
- a molecule or like terms is a chemical, biochemical or biological molecule, regardless of its size.
- molecules are of the type referred to as organic molecules (molecules containing carbon atoms, among others, connected by covalent bonds), although some molecules do not contain carbon (including simple molecular gases such as molecular oxygen and more complex molecules such as some sulfur-based polymers).
- the general term "molecule” includes numerous descriptive classes or groups of molecules, such as proteins, nucleic acids, carbohydrates, steroids, organic pharmaceuticals, small molecule, receptors, antibodies, and lipids.
- prevent means to stop a particular characteristic or condition. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce or inhibit. As used herein, something could be reduced but not inhibited or prevented, but something that is reduced could also be inhibited or prevented. Similarly, something could be reduced and inhibited, but not prevented. It is understood that where reduce, inhibit or prevent are used, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. Thus, if inhibits phosphorylation is disclosed, then reduces and prevents phosphorylation are also disclosed.
- Ranges can be expressed herein as from “about” one particular value, and/or to "about” another particular value. When such a range is expressed, some forms includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms some forms. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “ 10" is disclosed, then “about 10" is also disclosed.
- reduce or other forms of reduce means lowering of an event or characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to.
- reduceds phosphorylation means lowering the amount of phosphorylation that takes place relative to a standard or a control.
- Specifically interacts or like terms means that the interaction is beyond a background interaction.
- the background interaction can be determined by for example looking at the interaction with serum albumin.
- the "subject” can include, for example, domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal.
- livestock e.g., cattle, horses, pigs, sheep, goats, etc.
- laboratory animals e.g., mouse, rabbit, rat, guinea pig, etc.
- mammals non-human mammals
- primates primates
- non-human primates rodents
- rodents birds, reptiles, amphibians, fish, and any other animal.
- the subject can be a mammal such as a primate or a human.
- the subject can also be a non-human.
- Tissue or like terms refers to a collection of cells. Typically a tissue is obtained from a subject.
- a Radiation diagnostic composition is any composition which mimics the properties of a chromosome, such as an oligonucleotide. By mimics means has the property of being altered when exposed to radiation, such as UV radiation.
- Examples of radiation diagnostic compositions are compositions comprising one or more single nucleoside(s) and/or single nucleotide(s) in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series (or mixed series) where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
- oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotides (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same' compositions comprising one or more dinucleotides in a deoxy- and/or ribo- series (or mixed series and/or deoxy-ribo hybrids); compositions wherein the dinucleotide comprises thymidine- thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (TT), th
- a protection composition is any composition that reduces the amount of DNA damage to a cell, such as a sunscreen. It is understood that a protection composition can also be a composition that is being tested for a determination as to whether it reduces the amount of DNA damage to a cell, such as a composition that is being tested as to whether it is a sunscreen.
- FIG. 2 A representative flowchart according to the present disclosure is shown in Figure 2.
- the TT dinucleotide is the most sensitive to UV radiation [Marrot L, Meunier JR. Skin DNA photodamage and its biological consequences. J Am Acad Dermatol 2008;58(Suppl):S 139-48; Taylor J-S. Unraveling the molecular pathway from sunlight to skin cancer. Acc Chem Res 1994;27:76-82; Taylor J-S, Cohrs MP. DNA, light and Dewar pyrimidinones: the structure and biological significance of TpT3. J Am Chem Soc
- UVA-induced cyclobutane pyrimidine dimers form predominantly at thymine-thymine dipyrimidines and correlate with the mutation spectrum in rodent cells.
- a low-pressure mercury lamp UVP, Ace Glass Inc, Upland, CA
- TT dinucleotide was synthesized at 10 ⁇ scale on an ABI 392 DNA synthesizer, followed by HPLC purification. DNA concentration studies suggested that a lower
- TT dinucleotide i.e., 0.05 mmol/L in acetonitrile/water (90: 10) was used for all irradiation experiments. Irradiation experiments were designed so that the sun's UV damage on DNA was mimicked by using the UV damage produced by the mercury lamp on the synthesized TT dinucleotide.
- a round photolysis tube which contains a quartz filter with 200-nm cutoff, was used to hold the low-pressure mercury lamp (emission ⁇ 257 nm).
- This lamp and filter setting was chosen because the TT photodimer is the major photolesion product of the sun's UV irradiation (or damage) and the TT dinucleotide is most sensitive to the UVradiation around 260 nm, leading to maximal TT photodamage.
- this setting was selected to mimic intensified sunlight to amplify the sun's UV damaging effect and to easily and quickly monitor the sunscreen protective effect via reduction of the TT dimer formation.
- each sunscreen i.e., about 50 mg was applied evenly on different designated areas (same size) on the outside wall of the photolysis tube (thickness: i.e., 0.1-0.2 mm).
- Thickness i.e., 0.1-0.2 mm.
- a control experiment where no sunscreen was applied on the photolysis tube, was also performed each time.
- the Semi-Micro Quartz Cells (Starna Cells Inc, Atascadero, CA) containing the nucleotide solutions were placed, i.e., about 0.5 cm, away from the photolysis tube. These DNA samples were then exposed to the UV radiation from the UV lamp.
- the UV-irradiated samples were collected and analyzed using the Cary 300 Bio UV-visible Spectrophotometer (Clayton South, Australia), HPLC, or both.
- the time intervals were, i.e., 0, 10, 30, and 60 minutes.
- the UV spectra (200-400 nm) were obtained for all samples with and without sunscreen protection (SPF 15, 30, 45, and 70).
- the sunscreens were diluted. By diluting the sunscreens, larger differences between them can be observed. These diluted sunscreen experiments were carried out in a manner similar to the undiluted sunscreen experiments.
- UV spectrophotometer In the dilution experiments, approximately 100 mg of sunscreen was used for dilution with 1 mL of either water or petroleum ether (depending on the solubility of the sunscreens). During the UV irradiation, the UV spectra were recorded at 0-, 10- , 30-, and 60-minute time intervals using a UV spectrophotometer.
- buffer B contained 10 mmol/L of triethylammonium acetate (pH 7.1) in 50% acetonitrile.
- Each sample (20 ⁇ ⁇ , 0.1 mmol/L) was injected into HPLC with a gradient normally starting from 100% buffer A to 40% buffer B in 20 minutes, and the flow rate was 1.0 mL/min. Retention time for the TT dinucleotide was 15.9 minutes whereas the retention time for the lesion was approximately 11.2 minutes.
- Example 1 Protection of thymidine-thymidine dinucleotide by sunscreens against ultraviolet (UV) damage monitored by UV Spectrometry.
- the experiments were performed using a set of sunscreens.
- the control experiment (Fig. 3, 1), in which no sunscreen was applied on the photolysis tube, indicated that the UV absorbance of the dinucleotide in the solution decreases at 260 nm with an increase in the irradiation time. Meanwhile, upon the UV irradiation, the dinucleotide is severely damaged to form photolesions. Thus, as the irradiation time increases, the cross-linked TT photolesion that was monitored at 326 nm increases. Similarly, sunscreens with SPF 15, 30, 45, and 70 were examined (Fig. 3, 2 to 5 ).
- Example 2 Protection of thymidine-thymidine dinucleotide by sunscreens against ultraviolet (UV) damage monitored by High-performance liquid chromatography (HPLC).
- UV ultraviolet
- the TT dinucleotide was used as the mimic of DNA and was irradiated under UV light.
- the control experiment in which no sunscreen was applied on the photolysis tube, was performed as were the experiments with the application of sunscreens with different SPF values (15, 30, 45, and 70).
- the UV-irradiated samples were then analyzed by UV spectrophotometer and monitored by HPLC mainly at 4 different wavelengths: 250, 260, 290, and 326 nm.
- the samples were analyzed by HPLC at 4 different wavelengths before (0 minutes) and after (60 minutes) the UV irradiation.
- the HPLC analyses of the control samples with (for 60 minutes) and without (for 0 minutes) irradiation are shown in Figure 5.
- the TT pyrimidine (6-4) pyrimidone photoproduct has a typical absorption at 326 nm [Taylor J-
- HPLC is used to analyze the dinucleotide samples before and after the UV irradiation and with or without an application of sunscreen (Figures 5 to 7).
- Figures 5 to 7 HPLC analyses of the samples from the control experiment (profiles A to E) and the experiment using the SPF 70 sunscreen (profiles F and G) are shown.
- the control experiments the control experiments, the test experiments, the test experiments, the test experiment, the test experiment, the test experiment, the SPF 70 sunscreen, and G.
- HPLC analyses of the 0-, 10-, and 60-minute UV-exposed samples analyzed at 260 nm (profiles A to C) and the 10- and 60-minute UV-exposed samples analyzed at 326 nm (profiles D and E ) are presented.
- the exposure time increased the native TT dinucleotide, monitored at 260 nm, decomposed and decreased (profiles A to C).
- the lesion formation which was monitored at 326 nm, increased (profiles D and E ).
- the HPLC analyses of the 60-minute UV-exposed sample at 260 nm (profile F) and 326 nm (profile G) are presented.
- compositions comprising one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T (including, but not limited to, thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA
- UV, HPLC, or UV and HPLC methods and systems the effectiveness of sunscreens can be assessed easily, and the results are also consistent with the present SPF ranking of the commercial sunscreens.
- the natural TT dinucleotide is inexpensive.
- UV-vis and HPLC are readily available in many research and industrial laboratories.
- the disclosed methods and systems are cost-effective, convenient to perform, and allow for the establishment of quality and effectiveness cross-validation systems for comparing different sunscreen products.
- the disclosed methods and systems allow for high-throughput screening for highly efficient and nontoxic sunscreens with different ingredients.
- PK is involved in repairing a transient surge of DNA breaks induced by deceleration of DNA replication. J Mol Biol 2007;367:665-80.
- Moyal DD Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight- induced immunosuppression in human beings. J Am Acad Dermatol 2008;58(Suppl):S 149-54.
Abstract
Disclosed are compositions which can mimic DNA and/or RNA in cells of a subject and methods of using them as a substrate in testing efficacy of one or more compositions in reducing and/or preventing radiation, such as ultraviolet (UV) radiation-caused DNA and/or RNA damage of said subject. Also disclosed are systems related to the disclosed methods.
Description
ULTRAVIOLET AND HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY METHODS FOR THE EVALUATION OF
SUNSCREEN EFFICACY
RELATED TO PRIOR APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application 61/382, 154, filed September 13, 2010.
BACKGROUND
[0002] Sunlight plays many important roles for all organisms. Appropriate dosage of sunlight has tremendous biological benefits, such as photosynthesis in plants and vitamin D3 production in human skin [Nemanic MK, Whitney J, Arnaud S, Herbert S, Elias PM. Vitamin D3 production by cultured human keratinocytes and fibroblasts. Biochem Biophys Res Commun 1983 ; 115:444-50; Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin utr 2004;80: 1678S-88S], especially from exposure to ultraviolet (UV) B radiation. However, overexposure to sunlight will have devastating effects, such as cancer formation [Marrot L, Meunier JR. Skin DNA photodamage and its biological consequences. J Am Acad Dermatol 2008;58(Suppl):S139-48.], on human beings. Sunlight can cause DNA damage and gene mutation that leads to cancer formation, most typically skin cancer. There are many types of DNA lesions, including the cis- syn, trans-syn, (6-4), and Dewar pyrimidine-pyrimidine photolesions [Taylor J-S. Unraveling the molecular pathway from sunlight to skin cancer. Acc Chem Res 1994;27:76-82]. Among these possible pyrimidine nucleotide lesions, cis-syn and 6-4 photolesions are commonly observed [Taylor J-S, Cohrs MP. DNA, light and Dewar pyrimidinones: the structure and biological significance of TpT3. J Am Chem Soc 1987; 109:2834-5; Douki T, Court M, Cadet J. Electrospray-mass spectrometry characterization and measurement of far-UV-induced thymine photoproducts. J Photochem Photobiol B 2000;54: 145-54; Rochette PJ, Therrien JP, Drouin R, Perdiz D, Bastien N, Drobetsky EA, et al. UVA-induced cyclobutane pyrimidine dimers form predominantly at thymine-thymine dipyrimidines and correlate with the mutation spectrum in rodent cells. Nucleic Acids Res 2003 ;31 :2786-94]. Furthermore, the pyrimidine (6-4) pyrimidone photolesion is very mutagenic [Glas AF, Schneider S, Maul MJ, Hennecke U, Carell T. Crystal structure of the T(6-4)C lesion in complex with a (6-4) DNA photolyase and repair of UV-induced (6-4) and Dewar photolesions. Chemistry 2009; 15: 10387-96; Thomas M,
Guillaume D, Fourrey JL, Clivio P. Further insight in the photochemistry of DNA: structure of a
2-imidazolone (5-4) pyrimidone adduct derived from the mutagenic pyrimidine (6-4) pyrimidone photolesion by UV irradiation. J Am Chem Soc 2002; 124:2400-1; Young AR, Chadwick CA, Harrison GI, Hawk JL, Nikaido O, Potten CS. The in situ repair kinetics of epidermal thymine dimers and 6-4 photoproducts in human skin types I and II. J Invest
Dermatol 1996; 106: 1307-13], thereby leading to cancer formation.
[0003] Skin cancer is currently the most common type of human cancer in the United States [Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, et al. Myricetin suppresses UVB- induced skin cancer by targeting Fyn. Cancer Res 2008;68:6021-9]. Because DNA damage usually leads to cancer, tremendous attention has been given to damaged DNA repair research [Young AR, Chadwick CA, Harrison GI, Hawk JL, Nikaido O, Potten CS. The in situ repair kinetics of epidermal thymine dimers and 6-4 photoproducts in human skin types I and II. J Invest Dermatol 1996; 106: 1307-13; Shimura T, Martin MM, Torres MJ, Gu C, Pluth JM, DeBernardi MA, et al. DNA-PK is involved in repairing a transient surge of DNA breaks induced by deceleration of DNA replication. J Mol Biol 2007;367:665-80; Ueta E, Sasabe E, Yang Z, Osaki T, Yamamoto T. Enhancement of apoptotic damage of squamous cell carcinoma cells by inhibition of the mitochondrial DNA repairing system. Cancer Sci 2008;99:2230-7; Brissett NC, Doherty AJ. Repairing DNA double-strand breaks by the prokaryotic nonhomologous end-joining pathway. Biochem Soc Trans 2009;37:539-45]. In addition to endogenous DNA repair systems, DNA damage prevention, such as protection from UV radiation, can greatly minimize cancer formation. In general, skin application of sunscreen products, which block the UV from sunlight that causes the DNA damage, can effectively minimize DNA photolesion formation and prevent human skin cancer development. Many medical agencies have also recommended the use of sunscreens to temporarily protect the skin from sunlight exposure [Autier P, Boniol M, Dore JF. Sunscreen use and increased duration of intentional sun exposure: still a burning issue. Int J Cancer 2007; 121 : 1-5; Sayre RM, Dowdy JC, Lott DL, Marlowe E. Commentary on 'UVB-SPF' : the SPF labels of sunscreen products convey more than just UVB protection. Photodermatol Photoimmunol Photomed 2008;24:218-20].
[0004] To evaluate the effectiveness of sunscreen products, human subjects are normally used. Measurements of sunscreen effectiveness are performed by administering different sunscreen dosages to volunteers and then exposing them to sunlight [Young AR, Chadwick CA, Harrison GI, Hawk JL, Nikaido O, Potten CS. The in situ repair kinetics of epidermal thymine dimers and 6-4 photoproducts in human skin types I and II. J Invest Dermatol 1996; 106: 1307- 13; Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, et al. Myricetin suppresses UVB-
induced skin cancer by targeting Fyn. Cancer Res 2008;68:6021-9; Young AR, Potten CS, Chadwick CA, Murphy GM, Hawk JL, Cohen AJ. Photoprotection and 5-MOP
photochemoprotection from UVR-induced DNA damage in humans: the role of skin type. J Invest Dermatol 1991 ;97:942-8; Bissonnette R, Alias S, Moyal D, Provost N. Comparison of UVA protection afforded by high sun protection factor sunscreens. J Am Acad Dermatol
2000;43 : 1036-8; Young AR, Sheehan JM, Chadwick CA, Potten CS. Protection by ultraviolet A and B sunscreens against in situ dipyrimidine photolesions in human epidermis is comparable to protection against sunburn. J Invest Dermatol 2000; 115:37-41; Wagner JK, Parra EJ, L Norton H, Jovel C, Shriver MD. Skin responses to ultraviolet radiation: effects of constitutive pigmentation, sex, and ancestry. Pigment Cell Res 2002; 15: 385-90; Kelly DA, Seed PT, Young AR, Walker SL. A commercial sunscreen' s protection against ultraviolet radiation-induced immunosuppression is more than 50% lower than protection against sunburn in humans. J Invest Dermatol 2003; 120: 65-71; Dupuy A, Dunant A, Grob JJ. Randomized controlled trial testing the impact of high-protection sunscreens on sunexposure behavior. Arch Dermatol
2005; 141 :950-6; Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight-induced
immunosuppression in human beings. J Am Acad Dermatol 2008;58(Suppl):S 149-54]. This strategy is costly and allows for difficulty in generalizability because of age, sex, and race differences among the subjects. It is also difficult to cross-validate the quality and effectiveness of different sunscreen products. Moreover, with the traditional methods, it is difficult to develop highthroughput screening for highly efficient and less toxic sunscreens, which are needed to reduce cancer formation, especially skin cancer formation. Unfortunately, there is no simple, efficient, and quantitative methodology to address these cross-validation, high-throughput, and effectiveness questions using sunscreen products with human or animal subjects [Diffey BL, Tanner PR, Matts PJ, Nash JF. In vitro assessment of the broad-spectrum ultraviolet protection of sunscreen products. J Am Acad Dermatol 2000;43: 1024-35; Wang SQ, Stanfield JW, Osterwalder U. In vitro assessments of UVA protection by popular sunscreens available in the United States. J Am Acad Dermatol 2008;59:934-42].
[0005] Therefore, there is a need existing for the development of simple, convenient, efficient, effective, inexpensive, and/or quantitative systems and methods to evaluate the sunscreen efficacy.
SUMMARY
[0006] Disclosed are methods comprising the steps of: (a) providing an ultraviolet radiation (UV); (b) providing one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; (c) exposing said radiation diagnostic composition to said UV which passes through one or more protection compositions where said protection composition is positioned between said radiation diagnostic composition and said UV; and (d) analyzing DNA damage of said radiation diagnostic composition.
[0007] Also disclosed are systems comprising: (a) a first device to generate ultraviolet radiation; (b) a second device to hold one or more protection compositions; (c) a third device to contain one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; and (d) a fourth device to analyze DNA damage of said radiation diagnostic composition; wherein said second device is interposed between said first device and said third device, and said third device is interposed between said second device and said fourth device.
[0008] Further disclosed are radiation diagnostic compositions comprising one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same, which is/are dissolved in a suitable solvent with a suitable concentration.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several forms and together with the description illustrate the disclosed compounds and methods.
[0010] Figure 1 shows that thymidine-thymidine (TT) dinucleotide is sensitive to UV irradiation where various photolesions are formed under the UV irradiation. Structures of native and damaged thymidine-thymidine (TT) dinucleotides: Native TT dinucleotide (A), cis-syn photolesion (B), and (6-4) photolesion (C).
[0011] Figure 2 shows a representative flowchart of ultraviolet (UV) irradiation of natural thymidine-thymidine dinucleotide followed by high-performance liquid chromatography (HPLC) and UV analyses.
[0012] Figure 3 shows an example of protection of thymidine-thymidine dinucleotide by sunscreens against ultraviolet (UV) damage. UV irradiation for 0, 10, 30, and 60 minutes: without sunscreen protection (control) (1); and using sunscreen with sun protection factor (SPF) 15 (2); 30 (3); 45 (4); and 70 (5).
[0013] Figure 4 shows an example of Thymidine-thymidine dinucleotide protection by sunscreens against ultraviolet (UV) damage. UV irradiation for 60 minutes in presence and absence of sunscreens (sun protection factor [SPF] 15, 30, and 70): cyan bar, Control experiment; black bar, diluted sunscreens; and gray bar, undiluted sunscreens.
[0014] Figure 5 shows an example of High-performance liquid chromatography (HPLC) analysis of samples without sunscreen protection before and after ultraviolet irradiation.
Profiles A to D are from a sample without irradiation, monitored by HPLC at 250, 260, 290, and 326 nm, respectively. Profiles E to H are from the same sample irradiated for 60 minutes, monitored by HPLC at 250, 260, 290, and 326 nm, respectively.
[0015] Figure 6 shows an example of High-performance liquid chromatography (HPLC) analysis of the sample after 60-minute ultraviolet irradiation. HPLC profile of the sample monitored at 260 nm (A) and 326 nm (B). HPLC profile of thymidine-thymidine (TT) (6-4) photolesion at 260 nm (C). HPLC profile of TT (6-4) photolesion at 326 nm (D). Coinjection of the irradiated sample and TT (6-4) lesion monitored by HPLC at 326 nm (E).
[0016] Figure 7 shows an example of High-performance liquid chromatography (HPLC) analysis of dinucleotide samples ultraviolet irradiated in presence or absence of sunscreen. Profiles A to C are from 0-, 10-, and 60-minute, respectively, irradiated samples without sunscreen, monitored by HPLC at 260 nm. Profiles D and E are from 10- and 60-minute, respectively, irradiated samples without sunscreen, monitored by HPLC at 326 nm. Profiles F and G are from 60-minute irradiated sample protected by sun protection factor (SPF) 70, monitored at 260 nm and 326 nm, respectively. In all profiles, HPLC gradient runs from buffer A to 40% buffer B in 20 minutes.
DETAILED DESCRIPTION
[0017] Before the present compounds, compositions, articles, devices, systems, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods or specific treatment methods unless otherwise specified, or to particular
reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular forms only and is not intended to be limiting.
[0018] UVB sun protection factor (SPF) is normally assigned to different sunscreens products according to their sun protection effectiveness as determined by complicated strategies [systems and methods; Bissonnette R, Alias S, Moyal D, Provost N. Comparison of UVA protection afforded by high sun protection factor sunscreens. J Am Acad Dermatol
2000;43 : 1036-8; Wang SQ, Stanfield JW, Osterwalder U. In vitro assessments of UVA protection by popular sunscreens available in the United States. J Am Acad Dermatol
2008;59:934-42; Hexsel CL, Bangert SD, Hebert AA, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labeling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol 2008;59:316-23]. Because of consumer confusion about the rating of SPF numbers (sunscreen labels), consumer sunscreen SPF labeling is limited to SPF 50+ (ie, SPF > 60) in the European Union (countries). In 2007, the US Food and Drug Administration also proposed a similar grading system for UVB protection with SPF up to 50+, and 4-star grading for UVA protection [Hexsel CL, Bangert SD, Hebert AA, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labeling recommendations and combination sunscreen/insect repellent products. J Am Acad Dermatol 2008;59:316-23; Osterwalder U, Herzog B. Sun protection factors: world wide confusion. Br J Dermatol 2009; 161 (Suppl): 13-24]. Because thymidine-thymidine (TT) dinucleotide (Fig. 1) is sensitive to UV irradiation [Blagoev KB, Alexandrov BS, Goodwin EH, Bishop AR. Ultraviolet light induced changes in DNA dynamics may enhance TT-dimer recognition. DNA Repair (Amst) 2006;5:863-7; Rycyna RE, Alderfer JL. UV irradiation of nucleic acids: formation, purification and solution conformational analysis of the '6-4 lesion' of dTpdT. Nucleic Acids Res 1985; 13 :5949-63], and it forms various photolesions (including the deadly 6-4 photolesion), disclosed are simple methods using, in vitro nucleic acid molecules, such as a TT dinucleotide, radiation production and spectrophotometry, such as UV
spectrophotometry and analytical machinery, and high performance liquid chromatography (HPLC) analysis to address those validation and effectiveness challenges in the evaluation of sunscreen efficacy and to face the challenges of using human or animal subjects. Also disclosed are UV-HPLC systems that allow easy monitoring of the formation of various photolesions formed during the UV irradiation, for example, the thymidine (6-4) photolesion (pyrimidine(6-4) pyrimidone photoproduct), which is very mutagenic and has characteristic absorption at 320 nm.
The disclosed systems can be combined with traditional components of a synthetic TT dinucleotide (mimic of photosensitive DNA) and UV lamp (mimic of sunlight) to analyze commercially available sunscreens.
[0019] The disclosed methods and systems are simple sunscreen-analysis methods and systems, which are designed using nucleic acids, such as thymidinethymidine dinucleotides, ultraviolet spectrophotometer or highperformance liquid chromatography, or ultraviolet spectrophotometer and high performance liquid chromatography, avoids the use of human subjects to analyze the effectiveness of sunscreens. The disclosed radiation, such as ultraviolet and/or high-performance liquid chromatography methods and systems, can directly monitor types of DNA photolesions that are formed. To help prevent skin cancer caused by sunlight, the disclosed sunscreen-analysis methods and system provide assistance in choosing the most effective sunscreens for the skin health of consumers.
Methods
[0020] Disclosed are methods comprising the steps of: (a) providing a radiation, such as an ultraviolet radiation (UV); (b) providing one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a subject; (c) exposing said radiation diagnostic composition to said UV which passes through one or more protection compositions where said protection composition is positioned between said radiation diagnostic composition and said radiation, such as UV; and (d) analyzing DNA damage of said radiation diagnostic composition. In some forms, disclosed are methods which further comprise the step of comparing results obtained from step (d) with one or more control samples where said radiation diagnostic composition is exposed to said UV directly without the presence of said protection composition.
[0021] In some other forms, disclosed are methods which further comprise the step of identifying a protection composition that reduces and/or prevents ultraviolet (UV) radiation- caused DNA damage in a subject. In some forms, disclosed are methods wherein the step of identifying comprises assaying the presence of mutations in said radiation diagnostic composition. In some other forms, disclosed are methods which further comprise the step of screening efficacy of one or more protection compositions in reducing and/or preventing ultraviolet (UV) radiation-caused DNA damage in a subject.
[0022] In some other forms, disclosed are methods wherein said protection composition is sunscreen formulation, cosmetic formulation or a combination of sunscreen formulation and cosmetic formulation. In some other forms, disclosed are methods wherein said step (d) comprises performing the analysis of DNA damage by ultraviolet spectrophotometer, High-
performance liquid chromatography (HPLC), or a combination of said ultraviolet
spectrophotometer and said HPLC.
[0023] In some forms, disclosed are methods wherein said radiation diagnostic composition comprises one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same.
[0024] In some other forms, disclosed are methods wherein said radiation diagnostic composition comprises one or more dinucleotides in deoxy- and/or ribo- series, and/or deoxy- ribo hybrids. Said dinucleotide comprises thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
[0025] In other forms, disclosed are methods wherein said radiation diagnostic composition is dissolved in a solvent. In some forms, said solvent comprises water, acetonitrile, or a mixture of water and acetonitrile. In other forms, said solvent is a mixture of water and acetonitrile and the volume ratio between water and acetonitrile is from about 1 :20 to about 20: 1. In still some other forms, said volume ratio between water and acetonitrile is from about 1 :9 to about 9: 1.
[0026] In some forms, disclosed are methods wherein said radiation diagnostic composition is exposed to said UV from about 1 minute to about 48 hours. In some other forms, disclosed are methods wherein said radiation diagnostic composition is exposed to said UV about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes or 240 minutes. In some forms, disclosed are methods wherein said radiation diagnostic composition is dissolved in a solvent with a concentration of from about 0.000001 mmol/L to about 10 mmol/L. In some other forms, said radiation diagnostic composition is dissolved in a solvent with a concentration of from about 0.001 mmol/L to 0.5 mmol/L.
[0027] In some forms, disclosed are methods wherein said protection composition is provided in an amount of from about 0.01 mg to about 50 g. In some other forms, said
protection composition is provided and/or applied directly on a surface in an amount of from about 2 mg to about 200 mg. In some other forms, said protection composition is directly applied on a transparent surface (or support) that is placed between said radiation diagnostic composition and said UV. In some other forms, disclosed are methods wherein said protection composition is dissolved in a solvent. In some forms, disclosed are methods wherein said solvent comprises water, petroleum ether, or a mixture of water and petroleum ether. In some other forms, disclosed are methods wherein said mixture of water and petroleum ether has a volume ratio between water and petroleum ether from about 1 :20 to about 20: 1. In other forms, disclosed are methods wherein said protection composition is dissolved in a solvent with a concentration of from about 0.01 mg/mL to about lOOOmg/mL. In other forms, said protection composition is dissolved in a solvent with a concentration of from about 1 mg/ml to about 500mg/ml. In still some other forms, said protection composition is dissolved in a solvent with a concentration of from about 50 mg/ml to about 200mg/ml.
[0028] In some forms, disclosed are methods wherein said protection composition is a sunscreen formulation. In other forms, disclosed are methods wherein said sunscreen formulation has a sun protection factor (SPF) of from about 10 to about 100. In still some other forms, disclosed are methods wherein said sunscreen formulation has a SPF of about 15, 30, 45, or 70.
[0029] In some forms, disclosed are methods wherein said DNA damage comprises formation of DNA lesion. In other forms, disclosed are methods wherein said DNA lesion comprises cis-syn, trans-syn, TT pyrimidine (6-4) pyrimidone, Dewar pyrimidine-pyrimidine photolesion, or a mixture of the same. In still other forms, disclosed are methods wherein said DNA lesion comprises TT pyrimidine (6-4) pyrimidone photolesion.
[0030] In some forms, disclosed are methods wherein analysis of said DNA damage of said radiation diagnostic composition is conducted by monitoring the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in said radiation diagnostic composition after said radiation diagnostic composition is exposed to UV for a predetermined period of time. In other forms, disclosed are methods wherein analysis of said DNA damage of said radiation diagnostic compositions is conducted by monitoring the amount of TT dinucleotide preserved in said radiation diagnostic composition after said radiation diagnostic composition is exposed to UV for a predetermined period of time. In some forms, disclosed are methods wherein the UV- irradiated radiation diagnostic composition is analyzed by ultraviolet spectrophotometer and/or HPLC at wavelength of 250, 260, 290, 326 nm or a combination of the same. In other forms,
disclosed are methods wherein a representative ultraviolet absorption of TT pyrimidine (6-4) pyrimidone photolesion is at about 326 nm. In some other forms, disclosed are methods wherein a representative ultraviolet absorption of TT dinucleotide is at about 260 nm.
[0031] In some forms, disclosed are methods wherein a representative residence time of TT pyrimidine (6-4) pyrimidone photolesion in the HPLC is at about 1 1.2 minutes. In other forms, disclosed are methods wherein a representative residence time of TT dinucleotide in the HPLC is at about 15.9 minutes. In some forms, disclosed are methods wherein monitoring of the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in the UV-irridiated radiation diagnostic composition is conducted at one or more time intervals selected from the group consisting of 0, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180 and 240 minutes. In some other forms, disclosed are methods wherein said efficacy of said protection composition is indicated by the amount of TT pyrimidine (6-4) pyrimidone photolesion fromed in the UV-irridiated radiation diagnostic composition and/or the amount of TT dinucleotide preserved in the UV-irridiated radiation diagnostic composition.
[0032] In some forms, disclosed are methods wherein said efficacy of said protection composition as obtained from said method is consistent to SPF ranking of commercial sunscreens. In some other forms, disclosed are methods wherein said efficacy of said protection composition can be obtained without the use of human or animal subject. In some forms, disclosed are methods wherein said efficacy of said protection composition can be obtained within less than about 5, 10, 20, 30, 45, 60, 90 or 120 minutes. In some other forms, disclosed are methods wherein said testing of efficacy can be repeated with reliable results.
[0033] In some forms, disclosed are methods wherein said testing of efficacy can be cross- validated on different radiation diagnostic compositions and/or subjects. In some other forms, disclosed are methods wherein said testing of efficacy can be applied to a high-throughput screening for sunscreens. In some forms, disclosed are methods wherein said high-throughput screening for sunscreens comprises testing a plurality of sunscreens simultaneously or sequentially. In some other forms, disclosed are methods wherein said plurality of sunscreens comprises from about 5 to about 100,000 sunscreens. In some forms, disclosed are methods wherein said subject is a mammal.
Systems
[0034] Disclosed are systems comprising: (a) a first device to generate ultraviolet radiation; (b) a second device to hold one or more protection compositions; (c) a third device to contain one or more radiation diagnostic compositions representing and/or mimicing DNA in cells of a
subject; and (d) a fourth device to analyze DNA damage of said radiation diagnostic composition; wherein said second device is interposed between said first device and said third device, and said third device is interposed between said second device and said fourth device.
[0035] In some forms, disclosed are systems wherein said system is useful in identifying a protection composition that reduces and/or prevents ultraviolet (UV) radiation-caused DNA damage in a subject. In some other forms, disclosed are systems wherein said first device is an ultraviolet lamp. In some other forms, disclosed are systems wherein said first device is a low- pressure mercury lamp with emission ληΐίκ about 257 nm. In some forms, disclosed are systems wherein said second device is a photolysis tube. In some other forms, disclosed are systems wherein said second device is a photolysis tube having a quartz filter with 200-nm cutoff.
[0036] In some forms, disclosed are systems wherein said third device is a cuvette. In some forms, disclosed are systems wherein said fourth device is an ultraviolet spectrophotometer, High-performance liquid chromatography (HPLC), or a combination of said ultraviolet spectrophotometer and said HPLC. In some other forms, disclosed are systems wherein said radiation diagnostic composition comprises one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same. In some other forms, disclosed are systems wherein said radiation diagnostic composition comprises one or more dinucleotides in deoxy- and/or ribo- series. Said dinucleotide comprise thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine- guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
Compositions
[0037] Disclosed are radiation diagnostic compositions comprise one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or
ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
oligonucleotides in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same, which is/are dissolved in a suitable solvent with a suitable concentration. In some forms, disclosed are radiation diagnostic compositions wherein said radiation diagnostic compositions comprising one or more dinucleotides in deoxy- and/or ribo- series and/or deoxy-ribo hybrids. Said dinucleotide comprise thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine- guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
[0038] In some forms, disclosed are compositions wherein said suitable solvent is water, acetonitrile, or a mixture of water and acetonitrile with a suitable volume ratio. In other forms, disclosed are compositions wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is from about 1 :20 to about 20: 1. In some other forms, disclosed are compositions wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is from about 1 :9 to about 9: 1. In other forms, disclosed are compositions wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is about 1 :9. In some other forms, disclosed are compositions wherein said suitable concentration is from about 0.01 mmol/L to about 0.5 mmol/L. In still some other forms, disclosed are compositions wherein said suitable concentration is about 0.05 mmol/L. In some other forms, disclosed are compositions wherein said composition can mimic DNA in cells of a subject and be used as a substrate in testing efficacy of one or more formulations in reducing and/or preventing from ultraviolet radiation (UV) caused DNA damage of said subject.
Definitions
A. A, an, the
[0039] As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for
example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.
B. Cell
[0040] The term "cell" as used herein also refers to individual cells, cell lines, or radiation diagnostic compositions derived from such cells. A "culture" refers to a composition comprising isolated cells of the same or a different type. The term co-culture is used to designate when more than one type of cell are cultured together in the same dish with either full or partial contact with each other.
C. Compound
[0041] For the purposes of the present disclosure the terms "compound," "analog," and
"composition of matter" stand equally well for the chemical entities described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms "compound," "analog," and "composition of matter" are used interchangeably throughout the present specification.
D. Comprise
[0042] Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises," means "including but not limited to," and is not intended to exclude, for example, other additives, components, integers or steps.
E. Components
[0043] Disclosed are the components to be used to prepare the disclosed compositions as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C- D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of
additional steps that can be performed it is understood that each of these additional steps can be performed with any specific form or combination of forms of the disclosed methods.
F. Control
[0044] The terms "control" or "control levels" or "control cells" are defined as the standard by which a change is measured, for example, the controls are not subjected to the experiment, but are instead subjected to a defined set of parameters, or the controls are based on pre- or post- treatment levels. They can either be run in parallel with or before or after a test run, or they can be a pre-determined standard.
G. Higher
[0045] The terms "higher," "increases," "elevates," or "elevation" or like terms or variants of these terms, refer to increases above basal levels, e.g., as compared a control. The terms "low," "lower," "reduces," "decreases" or "reduction" or variation of these terms, refer to decreases below basal levels, e.g., as compared to a control. For example, basal levels are normal in vivo levels prior to, or in the absence of, or addition of an agent such as an agonist or antagonist to activity. For example, decreases or increases can be used to describe the binding of a molecule to a receptor. In this context, decreases would describe a situation of where the binding could be defined as having a Kd of 10"9 M, if this interaction decreased, meaning the binding lessened, the Kd could decrease to 10"6 M. It is understood that wherever one of these words is used it is also disclosed that it could be 1%, 5%, 10%, 20%, 50%, 100%, 500%, or 1000% increased or decreased from a control.
H. Inhibit
[0046] By "inhibit" or other forms of inhibit means to hinder or restrain a particular characteristic. It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, "inhibits phosphorylation" means hindering or restraining the amount of phosphorylation that takes place relative to a standard or a control.
I. Maintaining
[0047] The word "maintaining" or like words refers to continuing a state. In the context of a treatment, maintaining can be refer to less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.1% change from a control, such a basal level, often a level in the absence of a treatment or in the presence of tretament with a placebo or standard.
J. Material
[0048] Material is the tangible part of something (chemical, biochemical, biological, or mixed) that goes into the makeup of a physical object.
K. Modulate
[0049] The term modulate or like terms refers to its standard meaning of increasing or decreasing.
L. Substance
[0050] A substance or like terms is any physical object. A material is a substance.
Molecules, ligands, markers, cells, proteins, DNA and RNA can be considered substances. A machine or an article would be considered to be made of substances, rather than considered a substance themselves.
M. Molecule
[0051] As used herein, the terms "molecule" or like terms refers to a biological or biochemical or chemical entity that exists in the form of a chemical molecule or molecule with a definite molecular weight. A molecule or like terms is a chemical, biochemical or biological molecule, regardless of its size.
[0052] Many molecules are of the type referred to as organic molecules (molecules containing carbon atoms, among others, connected by covalent bonds), although some molecules do not contain carbon (including simple molecular gases such as molecular oxygen and more complex molecules such as some sulfur-based polymers). The general term "molecule" includes numerous descriptive classes or groups of molecules, such as proteins, nucleic acids, carbohydrates, steroids, organic pharmaceuticals, small molecule, receptors, antibodies, and lipids. When appropriate, one or more of these more descriptive terms (many of which, such as "protein," themselves describe overlapping groups of molecules) will be used herein because of application of the method to a subgroup of molecules, without detracting from the intent to have such molecules be representative of both the general class "molecules" and the named subclass, such as proteins. Unless specifically indicated, the word "molecule" would include the specific molecule and salts thereof, such as pharmaceutically acceptable salts.
N. Optionally
[0053] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
O. Prevent
[0054] By "prevent" or other forms of prevent means to stop a particular characteristic or condition. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce or inhibit. As used herein, something could be reduced but not inhibited or prevented, but something that is reduced could also be inhibited or prevented. Similarly, something could be reduced and inhibited, but not prevented. It is understood that where reduce, inhibit or prevent are used, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. Thus, if inhibits phosphorylation is disclosed, then reduces and prevents phosphorylation are also disclosed.
P. Ranges
[0055] Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, some forms includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms some forms. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value " 10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed that "less than or equal to" the value, "greater than or equal to the value" and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value " 10" is disclosed the "less than or equal to 10" as well as "greater than or equal to 10" is also disclosed. It is also understood that the throughout the application, data are provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular datum point " 10" and a particular datum point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 1 1, 12, 13, and 14 are also disclosed.
Q. Reduce
[0056] By "reduce" or other forms of reduce means lowering of an event or characteristic. It is understood that this is typically in relation to some standard or expected value, in other words
it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, "reduces phosphorylation" means lowering the amount of phosphorylation that takes place relative to a standard or a control.
R. References
[0057] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.
S. Specifically interacts
[0058] Specifically interacts or like terms means that the interaction is beyond a background interaction. The background interaction can be determined by for example looking at the interaction with serum albumin.
T. Subject
[0059] As used throughout, by a "subject" is meant an individual. Thus, the "subject" can include, for example, domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal. The subject can be a mammal such as a primate or a human. The subject can also be a non-human.
U. Tissue
[0060] Tissue or like terms refers to a collection of cells. Typically a tissue is obtained from a subject.
V. Radiation diagnostic composition
[0061] A Radiation diagnostic composition is any composition which mimics the properties of a chromosome, such as an oligonucleotide. By mimics means has the property of being altered when exposed to radiation, such as UV radiation. Examples of radiation diagnostic compositions are compositions comprising one or more single nucleoside(s) and/or single nucleotide(s) in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series (or mixed series) where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
oligonucleotides in deoxy- and/or ribo- series (or mixed series) where the number of the
nucleotides (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same' compositions comprising one or more dinucleotides in a deoxy- and/or ribo- series (or mixed series and/or deoxy-ribo hybrids); compositions wherein the dinucleotide comprises thymidine- thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
W. Protection composition
[0062] A protection composition is any composition that reduces the amount of DNA damage to a cell, such as a sunscreen. It is understood that a protection composition can also be a composition that is being tested for a determination as to whether it reduces the amount of DNA damage to a cell, such as a composition that is being tested as to whether it is a sunscreen.
Examples
[0063] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, systems and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.
A. Materials and General Procedures.
[0064] A representative flowchart according to the present disclosure is shown in Figure 2. Compared with other dinucleotides, the TT dinucleotide is the most sensitive to UV radiation [Marrot L, Meunier JR. Skin DNA photodamage and its biological consequences. J Am Acad Dermatol 2008;58(Suppl):S 139-48; Taylor J-S. Unraveling the molecular pathway from sunlight to skin cancer. Acc Chem Res 1994;27:76-82; Taylor J-S, Cohrs MP. DNA, light and Dewar pyrimidinones: the structure and biological significance of TpT3. J Am Chem Soc
1987; 109:2834-5; Douki T, Court M, Cadet J. Electrospray-mass spectrometry characterization and measurement of far-UV-induced thymine photoproducts. J Photochem Photobiol B
2000;54: 145-54; Rochette PJ, Therrien JP, Drouin R, Perdiz D, Bastien N, Drobetsky EA, et al.
UVA-induced cyclobutane pyrimidine dimers form predominantly at thymine-thymine dipyrimidines and correlate with the mutation spectrum in rodent cells. Nucleic Acids Res 2003;31 :2786-94; Glas AF, Schneider S, Maul MJ, Hennecke U, Carell T. Crystal structure of the T(6-4)C lesion in complex with a (6-4) DNA photolyase and repair of UV-induced (6-4) and Dewar photolesions. Chemistry 2009; 15: 10387-96]. To mimic sunlight effects, a low-pressure mercury lamp (UVP, Ace Glass Inc, Upland, CA) was used. In the experiments, TT
dinucleotide, dissolved in acetonitrile and water (9: 1), was radiated. The mixture of the organic and water solvents mimics a biological environment where large quantities of organic molecules are present. Moreover, the effectiveness of different sunscreens with various SPFs was evaluated. Subsequently, the irradiated samples were analyzed by HPLC and UV to investigate the DNA lesion formation.
[0065] TT dinucleotide was synthesized at 10 μιηοΐ scale on an ABI 392 DNA synthesizer, followed by HPLC purification. DNA concentration studies suggested that a lower
concentration generates the most lesion formation under UV irradiation. Thus, a solution of TT dinucleotide, i.e., 0.05 mmol/L in acetonitrile/water (90: 10) was used for all irradiation experiments. Irradiation experiments were designed so that the sun's UV damage on DNA was mimicked by using the UV damage produced by the mercury lamp on the synthesized TT dinucleotide. A round photolysis tube, which contains a quartz filter with 200-nm cutoff, was used to hold the low-pressure mercury lamp (emission λ 257 nm). This lamp and filter setting was chosen because the TT photodimer is the major photolesion product of the sun's UV irradiation (or damage) and the TT dinucleotide is most sensitive to the UVradiation around 260 nm, leading to maximal TT photodamage. Thus, this setting was selected to mimic intensified sunlight to amplify the sun's UV damaging effect and to easily and quickly monitor the sunscreen protective effect via reduction of the TT dimer formation.
[0066] The sunscreens were applied directly on the surface of the photolysis tube, and each sunscreen (i.e., about 50 mg) was applied evenly on different designated areas (same size) on the outside wall of the photolysis tube (thickness: i.e., 0.1-0.2 mm). Experiments were carried out simultaneously using, i.e., 4 to 6 sunscreens. In addition, a control experiment, where no sunscreen was applied on the photolysis tube, was also performed each time. The Semi-Micro Quartz Cells (Starna Cells Inc, Atascadero, CA) containing the nucleotide solutions were placed, i.e., about 0.5 cm, away from the photolysis tube. These DNA samples were then exposed to the UV radiation from the UV lamp. At various time intervals, the UV-irradiated samples were collected and analyzed using the Cary 300 Bio UV-visible Spectrophotometer (Clayton South,
Australia), HPLC, or both. The time intervals were, i.e., 0, 10, 30, and 60 minutes. The UV spectra (200-400 nm) were obtained for all samples with and without sunscreen protection (SPF 15, 30, 45, and 70). Moreover, to further differentiate the protection of sunscreens, the sunscreens were diluted. By diluting the sunscreens, larger differences between them can be observed. These diluted sunscreen experiments were carried out in a manner similar to the undiluted sunscreen experiments. In the dilution experiments, approximately 100 mg of sunscreen was used for dilution with 1 mL of either water or petroleum ether (depending on the solubility of the sunscreens). During the UV irradiation, the UV spectra were recorded at 0-, 10- , 30-, and 60-minute time intervals using a UV spectrophotometer.
[0067] After irradiation, the control samples that had been exposed to UV radiation for 0, 10, 30, and 60 minutes were analyzed by HPLC for the DNA lesion formation. These samples were analyzed mainly at two different wavelengths: 260 and 326 nm. To perform the HPLC analysis, the irradiated samples (100 μί, 0.05 mmol/L) were concentrated, and the volumes were adjusted to 50 (0.1 mmol/L), followed by injecting 20 into analytical HPLC (the reversed-phase HPLC column: XB-C18, 5 μιη, 4.6 x 250 mm, Welch Materials Inc). For the analysis, two buffers were used. Mobile phase buffer A contained 10 mmol/L of
triethylammonium acetate (pH 7.1), and buffer B contained 10 mmol/L of triethylammonium acetate (pH 7.1) in 50% acetonitrile. Each sample (20 μϊ^, 0.1 mmol/L) was injected into HPLC with a gradient normally starting from 100% buffer A to 40% buffer B in 20 minutes, and the flow rate was 1.0 mL/min. Retention time for the TT dinucleotide was 15.9 minutes whereas the retention time for the lesion was approximately 11.2 minutes.
B. Example 1 : Protection of thymidine-thymidine dinucleotide by sunscreens against ultraviolet (UV) damage monitored by UV Spectrometry.
[0068] The experiments (Fig. 3) were performed using a set of sunscreens. The control experiment (Fig. 3, 1), in which no sunscreen was applied on the photolysis tube, indicated that the UV absorbance of the dinucleotide in the solution decreases at 260 nm with an increase in the irradiation time. Meanwhile, upon the UV irradiation, the dinucleotide is severely damaged to form photolesions. Thus, as the irradiation time increases, the cross-linked TT photolesion that was monitored at 326 nm increases. Similarly, sunscreens with SPF 15, 30, 45, and 70 were examined (Fig. 3, 2 to 5 ). However, reduced absorbance changes in the 260 and 326 nm regions were observed for the analysis of sunscreens with higher SPF values. Moreover, when the sunscreen with SPF 70 was examined, no obvious DNA damage was observed under the
irradiation conditions. Thus, the UV spectrometry analysis appears to be a suitable approach to rapidly examine the effectiveness of sunscreens.
[0069] To differentiate between the sunscreens that have high SPF values (eg, SPF > 45), the experiments using diluted sunscreens were carried out. In these experiments, the commercial sunscreens (100 mg each) were primarily dissolved in 1 mL of petroleum ether or water. Then, the diluted sunscreens were applied on the photolysis tube to perform the irradiation process. The UVabsorbance was measured at 260 nm before and after the UV exposure. After the UV irradiation, the percentages of the undamaged TT dinucleotide were calculated and presented in Fig. 4. Each experiment was repeated at least 6 times.
[0070] In Figure 4, the control experiment, which was performed without applying any sunscreen, is shown as the cyan bar in the bar graph. The results from the experiments using the undiluted sunscreens are presented using the gray bars. On the other hand, the results from the experiments with the sunscreen dilutions are displayed using the black bars. As shown in Figure
4, the sunscreen protectiveness against the UV damage is reduced significantly after the dilution. Moreover, the differences in UV protection between the sunscreens become clearly
demonstrable after the dilution. In principle, it should be possible to greatly differentiate between sunscreens with high SPF values, such as 60 and 70, by even further dilution. As expected, more TT dinucleotide samples survived the UV irradiation when the sunscreens with higher SPF values were used. In other words, their protectiveness ranking by the UV analysis is consistent with the SPF commercial ranking.
C. Example 2: Protection of thymidine-thymidine dinucleotide by sunscreens against ultraviolet (UV) damage monitored by High-performance liquid chromatography (HPLC).
[0071] In the experiments, the TT dinucleotide was used as the mimic of DNA and was irradiated under UV light. The control experiment, in which no sunscreen was applied on the photolysis tube, was performed as were the experiments with the application of sunscreens with different SPF values (15, 30, 45, and 70). The UV-irradiated samples were then analyzed by UV spectrophotometer and monitored by HPLC mainly at 4 different wavelengths: 250, 260, 290, and 326 nm. In addition, the samples were analyzed by HPLC at 4 different wavelengths before (0 minutes) and after (60 minutes) the UV irradiation. The HPLC analyses of the control samples with (for 60 minutes) and without (for 0 minutes) irradiation are shown in Figure 5.
The TT pyrimidine (6-4) pyrimidone photoproduct has a typical absorption at 326 nm [Taylor J-
5. Unraveling the molecular pathway from sunlight to skin cancer. Acc Chem Res 1994;27:76- 824; Taylor J-S, Cohrs MP. DNA, light and Dewar pyrimidinones: the structure and biological
significance of TpT3. J Am Chem Soc 1987; 109:2834-5]. Because of to the lesion formation, only the irradiated samples showed a peak at 326 nm. To verify this lesion formation, the control sample that was irradiated for 60 minutes was further analyzed by the coinjection with the known and synthesized (6-4) photolesion sample [Osterwalder U, Herzog B. Sun protection factors: world wide confusion. Br J Dermatol 2009; 161(Suppl): 13-24]. This HPLC analysis at 260 and 326 nm confirmed the formation of the TT (6-4) photolesion (Fig. 6).
[0072] Furthermore, HPLC is used to analyze the dinucleotide samples before and after the UV irradiation and with or without an application of sunscreen (Figures 5 to 7). In Fig. 7, HPLC analyses of the samples from the control experiment (profiles A to E) and the experiment using the SPF 70 sunscreen (profiles F and G) are shown. For the control experiments, the
HPLC analyses of the 0-, 10-, and 60-minute UV-exposed samples analyzed at 260 nm (profiles A to C) and the 10- and 60-minute UV-exposed samples analyzed at 326 nm (profiles D and E ) are presented. As the exposure time increased the native TT dinucleotide, monitored at 260 nm, decomposed and decreased (profiles A to C). At the same time, the lesion formation, which was monitored at 326 nm, increased (profiles D and E ). For the experiments performed using the SPF 70 sunscreen, the HPLC analyses of the 60-minute UV-exposed sample at 260 nm (profile F) and 326 nm (profile G) are presented. Because the SPF 70 sunscreen can block the UV radiation effectively, the lesion formation was not detected. The experimental results indicate that both UV and HPLC analyses can be used to rapidly and effectively assess the protectiveness of sunscreens. Moreover, their protectiveness ranking by UV and HPLC analyses is consistent with the commercial SPF ranking.
Discussion and Summary
[0073] Disclosed are compositions comprising one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T (including, but not limited to, thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine- adenosine (AA), or adenosine-cytidine (AC) dinucleotide), one or more oligonucleotides in deoxy- and/or ribo- series where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the
oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same, dissolved in solution, i.e., the acetonitrile- water solution, can mimic DNA in cells and is sensitive to UV irradiation. Thus, it allows for the establishment of an ideal report system for studying the protectiveness of sunscreens. As a representative example of the present disclosure, on the basis of the TT reporting, it has been developed simple and rapid methods and systems via UV, HPLC or UV and HPLC for evaluation of the effectiveness of sunscreens without the use of human or animal subjects.
Using this UV, HPLC, or UV and HPLC methods and systems, the effectiveness of sunscreens can be assessed easily, and the results are also consistent with the present SPF ranking of the commercial sunscreens. Moreover, as a representative example of the present disclosure, the natural TT dinucleotide is inexpensive. In addition, UV-vis and HPLC are readily available in many research and industrial laboratories. For these reasons, the disclosed methods and systems are cost-effective, convenient to perform, and allow for the establishment of quality and effectiveness cross-validation systems for comparing different sunscreen products. Furthermore, the disclosed methods and systems allow for high-throughput screening for highly efficient and nontoxic sunscreens with different ingredients. These simple and effective methods and systems for analyzing sunscreens facilitate the development of new sunscreens and help reduce cancer occurrence and/or recurrence, especially skin cancers.
References
[0074] Nemanic MK, Whitney J, Arnaud S, Herbert S, Elias PM. Vitamin D3 production by cultured human keratinocytes and fibroblasts. Biochem Biophys Res Commun 1983; 1 15:444-50.
[0075] Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80: 1678S-88S.
[0076] Marrot L, Meunier JR. Skin DNA photodamage and its biological consequences. J Am Acad Dermatol 2008;58(Suppl):S 139-48.
[0077] Taylor J-S. Unraveling the molecular pathway from sunlight to skin cancer. Acc Chem Res 1994;27:76-82.
[0078] Taylor J-S, Cohrs MP. DNA, light and Dewar pyrimidinones: the structure and biological significance of TpT3. J Am Chem Soc 1987; 109:2834-5.
[0079] Douki T, Court M, Cadet J. Electrospray-mass spectrometry characterization and measurement of far-UV-induced thymine photoproducts. J Photochem Photobiol B
2000;54: 145-54.
[0080] Rochette PJ, Therrien JP, Drouin R, Perdiz D, Bastien N, Drobetsky EA, et al. UVA-induced cyclobutane pyrimidine dimers form predominantly at thymine-thymine dipyrimidines and correlate with the mutation spectrum in rodent cells. Nucleic Acids Res 2003;31 :2786-94.
[0081] Glas AF, Schneider S, Maul MJ, Hennecke U, Carell T. Crystal structure of the T(6- 4)C lesion in complex with a (6-4) DNA photo lyase and repair of UV-induced (6-4) and Dewar photolesions. Chemistry 2009; 15: 10387-96.
[0082] Thomas M, Guillaume D, Fourrey JL, Clivio P. Further insight in the
photochemistry of DNA: structure of a 2-imidazolone (5-4) pyrimidone adduct derived from the mutagenic pyrimidine (6-4) pyrimidone photolesion by UV irradiation. J Am Chem Soc 2002; 124:2400-1.
[0083] Young AR, Chadwick CA, Harrison GI, Hawk JL, Nikaido O, Potten CS. The in situ repair kinetics of epidermal thymine dimers and 6-4 photoproducts in human skin types I and II.
J Invest Dermatol 1996; 106: 1307-13.
[0084] Jung SK, Lee KW, Byun S, Kang NJ, Lim SH, Heo YS, et al. Myricetin suppresses
UVB-induced skin cancer by targeting Fyn. Cancer Res 2008;68:6021-9.
[0085] Shimura T, Martin MM, Torres MJ, Gu C, Pluth JM, DeBernardi MA, et al. DNA-
PK is involved in repairing a transient surge of DNA breaks induced by deceleration of DNA replication. J Mol Biol 2007;367:665-80.
[0086] Ueta E, Sasabe E, Yang Z, Osaki T, Yamamoto T. Enhancement of apoptotic damage of squamous cell carcinoma cells by inhibition of the mitochondrial DNA repairing system. Cancer Sci 2008;99:2230-7.
[0087] Brissett NC, Doherty AJ. Repairing DNA double-strand breaks by the prokaryotic non-homologous end-joining pathway. Biochem Soc Trans 2009;37:539-45.
[0088] Autier P, Boniol M, Dore JF. Sunscreen use and increased duration of intentional sun exposure: still a burning issue. Int J Cancer 2007; 121 : 1-5.
[0089] Sayre RM, Dowdy JC, Lott DL, Marlowe E. Commentary on 'UVB-SPF' : the SPF labels of sunscreen products convey more than just UVB protection. Photodermatol
Photoimmunol Photomed 2008;24:218-20.
[0090] Young AR, Potten CS, Chadwick CA, Murphy GM, Hawk JL, Cohen AJ.
Photoprotection and 5 -MOP photochemoprotection from UVR- induced DNA damage in humans: the role of skin type. J Invest Dermatol 1991;97:942-8.
[0091] Bissonnette R, Alias S, Moyal D, Provost N. Comparison of UVA protection afforded by high sun protection factor sunscreens. J Am Acad Dermatol 2000;43 : 1036-8.
[0092] Young AR, Sheehan JM, Chadwick CA, Potten CS. Protection by ultraviolet A and B sunscreens against in situ dipyrimidine photolesions in human epidermis is comparable to protection against sunburn. J Invest Dermatol 2000; 115:37-41.
[0093] Wagner JK, Parra EJ, L Norton H, Jovel C, Shriver MD. Skin responses to ultraviolet radiation: effects of constitutive pigmentation, sex, and ancestry. Pigment Cell Res 2002; 15: 385-90.
[0094] Kelly DA, Seed PT, Young AR, Walker SL. A commercial sunscreen' s protection against ultraviolet radiation- induced immunosuppression is more than 50% lower than protection against sunburn in humans. J Invest Dermatol 2003; 120: 65-71.
[0095] Dupuy A, Dunant A, Grob JJ. Randomized controlled trial testing the impact of high-protection sunscreens on sunexposure behavior. Arch Dermatol 2005; 141 :950-6.
[0096] Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight- induced immunosuppression in human beings. J Am Acad Dermatol 2008;58(Suppl):S 149-54.
[0097] Diffey BL, Tanner PR, Matts PJ, Nash JF. In vitro assessment of the broad-spectrum ultraviolet protection of sunscreen products. J Am Acad Dermatol 2000;43: 1024-35.
[0098] Wang SQ, Stanfield JW, Osterwalder U. In vitro assessments of UVA protection by popular sunscreens available in the United States. J Am Acad Dermatol 2008;59:934-42.
[0099] Hexsel CL, Bangert SD, Hebert AA, Lim HW. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labeling recommendations and combination
sunscreen/insect repellent products. J Am Acad Dermatol 2008;59:316-23.
[00100] Osterwalder U, Herzog B. Sun protection factors: world wide confusion. Br J Dermatol 2009; 161(Suppl): 13-24.
[00101] Blagoev KB, Alexandrov BS, Goodwin EH, Bishop AR. Ultraviolet light induced changes in DNA dynamics may enhance TT-dimer recognition. DNA Repair (Amst)
2006;5:863-7.
[00102] Rycyna RE, Alderfer JL. UV irradiation of nucleic acids: formation, purification and solution conformational analysis of the '6-4 lesion' of dTpdT. Nucleic Acids Res 1985; 13:5949- 63.
Claims
1. A method comprising the steps of:
(a) providing ultraviolet radiation (UV);
(b) providing one or more radiation diagnostic composition;
(c) exposing said radiation diagnostic composition to said radiation which passes through one or more protection compositions where said protection composition is positioned between said radiation diagnostic composition and said radiation; and
(d) analyzing DNA and/or RNA damage of said radiation diagnostic composition.
2. The method of claim 1, further comprising the step of comparing results obtained from step (d) with one or more control samples where said radiation diagnostic composition is exposed to said radiation directly without the presence of said protection composition.
3. The method of claim 1 or claim 2, further comprising the step of identifying a said protection composition that reduces and/or prevents ultraviolet (UV) radiation-caused DNA and/or RNA damage in a subject.
4. The method of claim 3, wherein the step of identifying comprises assaying the presence of DNA mutations in said radiation diagnostic composition.
5. The method of any one of claims 1 to 4, further comprising the step of screening efficacy of one or more said protection compositions in reducing and/or preventing ultraviolet (UV) radiation-caused DNA damage in a subject.
6. The method of any one of claims 1 to 5, wherein said protection composition is sunscreen formulation, cosmetic formulation or a combination of sunscreen formulation and cosmetic formulation.
7. The method of any one of claims 1 to 6, wherein said step (d) comprises performing the analysis of DNA and/or RNA damage by ultraviolet spectrophotometer, High-performance liquid chromatography (HPLC), or a combination of said ultraviolet spectrophotometer and said HPLC.
8. The method of any one of claims 1 - 7, wherein said radiation diagnostic composition comprises one or more single nucleoside(s) and/or single nucleotide(s) in deoxy - and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more oligonucleotides in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the number of the nucleotides (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same.
9. The method of any one of claims 1 - 8, wherein said radiation diagnostic composition comprises one or more dinucleotides in a deoxy- and/or ribo- series and/or deoxy- ribo hybrids.
10. The method of any one of claims 1 - 9, wherein said dinucleotide comprises thymidine-thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine- adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine- adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
1 1. The method of any one of claims 1 - 10, wherein said radiation diagnostic composition is dissolved in a solvent.
12. The method of any one of claims 1 - 1 1, wherein said solvent comprises water, acetonitrile, or a mixture of water and acetonitrile.
13. The method of any one of claims 1 - 12, wherein said solvent is a mixture of water and acetonitrile and the volume ratio between water and acetonitrile is from about 1 :20 to about 20: 1.
14. The method of any one of claims 1 - 13, wherein said volume ratio between water and acetonitrile is from about 1 :9 to about 9: 1.
15. The method of any one of claims 1 - 14, wherein said radiation diagnostic composition is exposed to said radiation from about 1 minute to about 48 hours.
16. The method of any one of claims 1 - 15, wherein said radiation diagnostic composition is exposed to said radiation about 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes or 240 minutes.
17. The method of any one of claims 1 - 16, wherein said radiation diagnostic composition is dissolved in a solvent with a concentration of from about 0.000001 mmol/L to about 10 mmol/L.
18. The method of any one of claims 1 - 17, wherein said radiation diagnostic composition is dissolved in a solvent with a concentration of from about 0.001 mmol/L to 0.5 mmol/L.
19. The method of any one of claims 1 - 18, wherein said protection composition is provided and/or applied directly on a surface in an amount of from about 0.01 mg to about 50 g-
20. The method of any one of claims 1 - 19, wherein said protection composition is provided and/or applied in an amount of from about 2 mg to about 200 mg.
21. The method of any one of claims 1 - 20, wherein said protection composition is dissolved in a solvent.
22. The method of any one of claims 1 - 21, wherein said solvent comprises water, petroleum ether, or a mixture of water and petroleum ether.
23. The method of any one of claims 1-22, wherein said mixture of water and petroleum ether has a volume ratio between water and petroleum ether from about 1 :20 to about 20: 1.
24. The method of any one of claims 1-23, wherein said protection composition is dissolved in a solvent with a concentration of from about 0.01 mg/ml to about lOOOmg/ml.
25. The method of any one of claims 1-24, wherein said protection composition is dissolved in a solvent with a concentration of from about 1 mg/ml to about 500mg/ml.
26. The method of any one of claims 1-25 wherein said protection composition is dissolved in a solvent with a concentration of from about 50 mg/ml to about 200mg/ml.
27. The method of any one of claims 1-26, wherein said protection composition is a sunscreen formulation.
28. The method of any one of claims 1-27, wherein said sunscreen formulation has a sun protection factor (SPF) of from about 10 to about 100.
29. The method of any one of claims 1-28, wherein said sunscreen formulation has a SPF of about 15, 30, 45, or 70.
30. The method of any one of claims 1-29, wherein said DNA damage comprises formation of DNA lesion.
31. The method of any one of claims 1-30, wherein said DNA lesion comprises cis-syn, trans-syn, TT pyrimidine (6-4) pyrimidone, Dewar pyrimidine-pyrimidine photolesion, or a mixture thereof.
32. The method of any one of claims 1-31, wherein said DNA lesion comprises TT pyrimidine (6-4) pyrimidone photolesion.
33. The method of any one of claims 1-32, wherein analysis of said DNA and/or RNA damage of said radiation diagnostic composition is conducted by monitoring the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in said radiation diagnostic composition after said radiation diagnostic composition is exposed to said radiation for a predetermined period of time.
34. The method of any one of claims 1-33, wherein analysis of said DNA and/or RNA damage of said radiation diagnostic composition is conducted by monitoring the amount of TT dinucleotide preserved in said radiation diagnostic composition after said radiation diagnostic composition is exposed to said radiation for a predetermined period of time.
35. The method of any one of claims 1-34, wherein the UV-irradiated said radiation diagnostic composition is analyzed by ultraviolet spectrophotometer and/or HPLC at wavelength of 250, 260, 290, 326 nm or a combination of the same.
36. The method of any one of claims 1-35, wherein a representative ultraviolet absorption of TT pyrimidine (6-4) pyrimidone photolesion is at about 326 nm.
37. The method of any one of claims 1-36, wherein a representative ultraviolet absorption of TT dinucleotide is at about 260 nm.
38. The method of any one of claims 1-37, wherein a representative residence time of TT pyrimidine (6-4) pyrimidone photolesion in the HPLC is at about 11.2 minutes.
39. The method of any one of claims 1-38, wherein a representative residence time of TT dinucleotide in the HPLC is at about 15.9 minutes.
40. The method of any one of claims 1-39, wherein monitoring of the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in the UV-irradiated said radiation diagnostic composition is conducted at one or more time intervals selected from the group consisting of 0, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180 and 240 minutes.
41. The method of any one of claims 1 -40, wherein said efficacy of said protection composition is indicated by the amount of TT pyrimidine (6-4) pyrimidone photolesion formed in the UV-irradiated said radiation diagnostic composition and/or the amount of TT dinucleotide preserved in the UV-irradiated said radiation diagnostic composition.
42. The method of any one of claims 1-41, wherein said efficacy of said protection composition as obtained from said method is consistent to SPF ranking of commercial sunscreens.
43. The method of any one of claims 1-42, wherein said efficacy of said protection composition can be obtained without the use of human or animal subject.
44. The method of any one of claims 1-43, wherein said efficacy of said protection composition can be obtained within less than about 5, 10, 20, 30, 45, 60, 90 or 120 minutes.
45. The method of any one of claims 1-44, wherein said testing of efficacy can be repeated with reliable results.
46. The method of any one of claims 1-45, wherein said testing of efficacy can be cross-validated on different said protection compositions and/or subjects.
47. The method of any one of claims 1-46, wherein said testing of efficacy can be applied to a high-throughput screening for sunscreens.
48. The method of any one of claims 1-47, wherein said high-throughput screening for sunscreens comprises testing a plurality of sunscreens simultaneously or sequentially.
49. The method of any one of claims 1-48, wherein said plurality of sunscreens comprises from about 5 to about 100,000 sunscreens.
50. The method of claims 1-49, wherein said subject is a mammal.
51. A system comprising:
(a) a first device to generate ultraviolet radiation;
(b) a second device to hold one or more protection compositions;
(c) a third device to contain one or more radiation diagnostic compositions; and
(d) a fourth device to analyze DNA and/or RNA damage of said radiation diagnostic composition; wherein said second device is interposed between said first device and said third device, and said third device is interposed between said second device and said fourth device.
52. The system of claim 51, wherein said system is useful in identifying a said protection composition that reduces and/or prevents ultraviolet (UV) radiation-caused DNA and/or RNA damage in a subject.
53. The system of claim 51 or 52, wherein said system is useful in screening efficacy of one or more said protection compositions in reducing and/or preventing ultraviolet (UV) radiation-caused DNA and/or RNA damage in a subject.
54. The system of any one of claims 51-53, wherein said first device is an ultraviolet lamp or a solar simulator.
55. The system of any one of claims 51-54, wherein said first device is a low-pressure mercury lamp with emission ληιαχ about 257 nm.
56. The system of any one of claims 51-55, wherein said second device is a photolysis tube.
57. The system of any one of claims 51-56, wherein said second device is a photolysis tube having a quartz filter with 200-nm cutoff.
58. The system of any one of claims 51-57, wherein said third device is a cuvette.
59. The system of any one of claims 51-58, wherein said fourth device is an ultraviolet spectrophotometer, High-performance liquid chromatography (HPLC), or a combination of said ultraviolet spectrophotometer and said HPLC.
60. The system of any one of claims 51-59, wherein said radiation diagnostic composition comprises one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more oligonucleotides in deoxy - and/or ribo- series and/or deoxy-ribo hybrids where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same.
61. The system of any one of claims 51 -60, wherein said radiation diagnostic composition comprises one or more dinucleotides in deoxy- and/or ribo- series and/or deoxy- ribo hybrids where said dinucleotide comprising thymidine-thymidine (TT), thymidine- cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine-cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
62. A composition comprising one or more single nucleoside and/or single nucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base is A, G, C, U or T, one or more dinucleotide in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the heterocyclic amine base of each of the nucleotide of the dinucleotide is independently selected from a group consisting of A, G, C, U and T, one or more
oligonucleotides in deoxy- and/or ribo- series and/or deoxy-ribo hybrids where the number of the nucleotide (nt) forming the oligonucleotide is from 3 to 100 and where the heterocyclic amine base of each of the nucleotide of the oligonucleotide is independently selected from a group consisting of A, G, C, U and T, an artificial skin culture, or a combination of the same, which is/are dissolved in a suitable solvent with a suitable concentration.
63. The composition of claim 62, wherein said dinucleotide comprising thymidine- thymidine (TT), thymidine-cytidine (TC), thymidine-guanosine (TG), thymidine-adenosine (TA), thymidine-uridine (TU), uridine- uridine (UU], uridine-thymidine (UT), cytidine- cytidine (CC), cytidine-adenosine (CA), guanosine- guanosine (GG), guanosine-adenosine (GA), adenosine-adenosine (AA), or adenosine-cytidine (AC) dinucleotide.
64. The composition of claim 62 or claim 63, wherein said suitable solvent is water, acetonitrile, or a mixture of water and acetonitrile with a suitable volume ratio.
65. The composition of any one of claims 62-64, wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is from about 1 :20 to about 20: 1.
66. The composition of any one of claims 62-65, wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is from about 1 :9 to about 9: 1.
67. The composition of any one of claims 62-66, wherein said suitable solvent is a mixture of water and acetonitrile wherein the volume ratio between water and acetonitrile is about 1 :9.
68. The composition of any one of claims 62-67, wherein said suitable concentration is from about 0.01 mmol/L to about 0.5 mmol/L.
69. The composition of any one of claims 62-68, wherein said suitable concentration is about 0.05 mmol/L.
70. The composition of any one of claims 62-69, wherein said composition can mimic DNA and/or RNA in cells of a subject and be used as a substrate in testing efficacy of one or more compositions in reducing and/or preventing from ultraviolet (UV) radiation-caused DNA and/or RNA damage of said subject.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/823,028 US10073033B2 (en) | 2010-09-13 | 2011-09-13 | Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy |
| US16/100,368 US20190003966A1 (en) | 2010-09-13 | 2018-08-10 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38215410P | 2010-09-13 | 2010-09-13 | |
| US61/382,154 | 2010-09-13 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/823,028 A-371-Of-International US10073033B2 (en) | 2010-09-13 | 2011-09-13 | Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy |
| US16/100,368 Continuation US20190003966A1 (en) | 2010-09-13 | 2018-08-10 | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012037158A2 true WO2012037158A2 (en) | 2012-03-22 |
| WO2012037158A3 WO2012037158A3 (en) | 2012-05-18 |
Family
ID=45832208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/051448 WO2012037158A2 (en) | 2010-09-13 | 2011-09-13 | Ultraviolet and high-performance liquid chromatography methods for the evaluation of sunscreen efficacy |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US10073033B2 (en) |
| WO (1) | WO2012037158A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108709949A (en) * | 2018-05-29 | 2018-10-26 | 江西国药有限责任公司 | A kind of detection method of the fermentation cordyceps Cs-4 prepared slices of Chinese crude drugs |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410333B1 (en) * | 1997-06-17 | 2002-06-25 | UNIVERSITé LAVAL | Assessment of human skin damage following exposure to harmful agents |
| US20080056995A1 (en) * | 2006-07-11 | 2008-03-06 | Timmins Graham S | System and methods for measuring a skin protection factor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691158A (en) * | 1993-10-15 | 1997-11-25 | Mary Kay Cosmetics, Inc. | System and method for determining efficacy of sunscreen formulations |
| US20020045941A1 (en) * | 2000-05-19 | 2002-04-18 | Shiseido Company, Ltd. | Artificial skin and method for evaluating UV screening agent by use of the same |
| US6743449B2 (en) * | 2002-02-13 | 2004-06-01 | Skinceuticals, Inc. | Topical composition comprising olive leaf extract |
-
2011
- 2011-09-13 WO PCT/US2011/051448 patent/WO2012037158A2/en active Application Filing
- 2011-09-13 US US13/823,028 patent/US10073033B2/en not_active Expired - Fee Related
-
2018
- 2018-08-10 US US16/100,368 patent/US20190003966A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410333B1 (en) * | 1997-06-17 | 2002-06-25 | UNIVERSITé LAVAL | Assessment of human skin damage following exposure to harmful agents |
| US20080056995A1 (en) * | 2006-07-11 | 2008-03-06 | Timmins Graham S | System and methods for measuring a skin protection factor |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108709949A (en) * | 2018-05-29 | 2018-10-26 | 江西国药有限责任公司 | A kind of detection method of the fermentation cordyceps Cs-4 prepared slices of Chinese crude drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130183765A1 (en) | 2013-07-18 |
| US10073033B2 (en) | 2018-09-11 |
| WO2012037158A3 (en) | 2012-05-18 |
| US20190003966A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pecourt et al. | DNA excited-state dynamics: Ultrafast internal conversion and vibrational cooling in a series of nucleosides | |
| Roy | Impact of UV radiation on genome stability and human health | |
| Schmidt et al. | Mechanism of photocleavage of (coumarin-4-yl) methyl esters | |
| Wani et al. | A potential anticancer dihydropyrimidine derivative and its protein binding mechanism by multispectroscopic, molecular docking and molecular dynamic simulation along with its in-silico toxicity and metabolic profile | |
| Zhang et al. | Probing the binding of insecticide permethrin to calf thymus DNA by spectroscopic techniques merging with chemometrics method | |
| Dizdaroglu et al. | Measurement of oxidatively induced DNA damage and its repair, by mass spectrometric techniques | |
| Naseri et al. | Interaction of norfloxacin with bovine serum albumin studied by different spectrometric methods; displacement studies, molecular modeling and chemometrics approaches | |
| Qu et al. | Phototransformation rates and mechanisms for synthetic hormone growth promoters used in animal agriculture | |
| Lhiaubet-Vallet et al. | Triplet excited fluoroquinolones as mediators for thymine cyclobutane dimer formation in DNA | |
| Lelièvre et al. | The EpiSkin phototoxicity assay (EPA): development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency | |
| Flyunt et al. | Fate of the 2 ‘-deoxyadenosin-5 ‘-Yl radical under anaerobic conditions | |
| Wang et al. | Excited state decay pathways of 2′-deoxy-5-methylcytidine and deoxycytidine revisited in solution: a comprehensive kinetic study by femtosecond transient absorption | |
| Chi et al. | New insights into the characterization of the binding of tetracycline analogues with lysozyme: a biophysical study | |
| Poinar | The genetic secrets some fossils hold | |
| Bobrowski et al. | Sulfur radical cation− peptide bond complex in the one-electron oxidation of S-Methylglutathione | |
| Liao et al. | Multi-spectroscopic and molecular docking studies of human serum albumin interactions with sulfametoxydiazine and sulfamonomethoxine | |
| Daberkow et al. | Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning | |
| US20190003966A1 (en) | Ultraviolet and High-Performance Liquid Chromatography Methods for the Evaluation of Sunscreen Efficacy | |
| Espino et al. | Chemical penetration enhancers increase hydrogen peroxide uptake in C. elegans for in vivo fast photochemical oxidation of proteins | |
| Su et al. | Study on the binding mechanism of thiamethoxam with three model proteins: spectroscopic studies and theoretical simulations | |
| Starciuc et al. | Water content thresholds in glycerol/water system: Low-and high-wavenumber Raman spectroscopy study | |
| Fu et al. | Free radical scavenging and radioprotective effects of carnosine and anserine | |
| Swindell et al. | Tetrahexyldecyl ascorbate (THDC) degrades rapidly under oxidative stress but can be stabilized by acetyl zingerone to enhance collagen production and antioxidant effects | |
| Teng et al. | Molecular interaction mechanism between 2-mercaptobenzimidazole and copper-zinc superoxide dismutase | |
| Montgomery et al. | Interspecies Differences in 6PPD-Quinone Toxicity Across Seven Fish Species: Metabolite Identification and Semiquantification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11825814 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13823028 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11825814 Country of ref document: EP Kind code of ref document: A2 |